These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 3240548)

  • 1. Liposomal sustained-release delivery systems for intravenous injection. IV. Antitumor activity of newly synthesized lipophilic 1-beta-D-arabinofuranosylcytosine prodrug-bearing liposomes.
    Tokunaga Y; Iwasa T; Fujisaki J; Sawai S; Kagayama A
    Chem Pharm Bull (Tokyo); 1988 Sep; 36(9):3574-83. PubMed ID: 3240548
    [No Abstract]   [Full Text] [Related]  

  • 2. Liposomal sustained-release delivery systems for intravenous injection V. Biological disposition of liposome-entrapped lipophilic prodrug of 1-beta-D-arabinofuranosylcytosine.
    Tokunaga Y; Iwasa T; Fujisaki J; Sawai S; Kagayama A
    Chem Pharm Bull (Tokyo); 1988 Oct; 36(10):4060-7. PubMed ID: 3245983
    [No Abstract]   [Full Text] [Related]  

  • 3. Liposomal sustained-release delivery systems for intravenous injection. III. Antitumor activity of lipophilic mitomycin C prodrug-bearing liposomes.
    Tokunaga Y; Iwasa T; Fujisaki J; Sawai S; Kagayama A
    Chem Pharm Bull (Tokyo); 1988 Sep; 36(9):3565-73. PubMed ID: 3149215
    [No Abstract]   [Full Text] [Related]  

  • 4. Liposomal sustained-release delivery systems for intravenous injection. II. Design of liposome carriers and blood disposition of lipophilic mitomycin C prodrug-bearing liposomes.
    Tokunaga Y; Iwasa T; Fujisaki J; Sawai S; Kagayama A
    Chem Pharm Bull (Tokyo); 1988 Sep; 36(9):3557-64. PubMed ID: 3149214
    [No Abstract]   [Full Text] [Related]  

  • 5. Synthesis and structure-activity studies in vivo of liposomal phospholipid-N4-palmitoyl- and N4-hexadecyl-1-beta-D-arabinofuranosylcytosine conjugates.
    Schott H; Schwendener RA
    Anticancer Drug Des; 1996 Sep; 11(6):451-62. PubMed ID: 8836110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes.
    Rubas W; Supersaxo A; Weder HG; Hartmann HR; Hengartner H; Schott H; Schwendener R
    Int J Cancer; 1986 Jan; 37(1):149-54. PubMed ID: 3941019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment of intravenously implanted Lewis lung carcinoma with two sustained release forms of 1-beta-D-arabinofuranosylcytosine.
    Rahman YE; Patel KR; Cerny EA; Maccoss M
    Eur J Cancer Clin Oncol; 1984 Aug; 20(8):1105-12. PubMed ID: 6540691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of macromolecule-bound derivatives of a peptidyl-1-beta-D-arabinofuranosylcytosine prodrug.
    Balajthy Z
    Drug Metab Lett; 2008 Apr; 2(2):83-9. PubMed ID: 19356076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of liposome type and route of administration in the antitumor activity of liposome-entrapped 1-beta-D-arabinofuranosylcytosine against mouse L1210 leukemia.
    Rustum YM; Dave C; Mayhew E; Papahadjopoulos D
    Cancer Res; 1979 Apr; 39(4):1390-5. PubMed ID: 421223
    [No Abstract]   [Full Text] [Related]  

  • 10. Interactions with human blood in vitro and pharmacokinetic properties in mice of liposomal N4-octadecyl-1-beta-D-arabinofuranosylcytosine, a new anticancer drug.
    Koller-Lucae SK; Schott H; Schwendener RA
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1572-80. PubMed ID: 9316874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the conjugate between N4-(4-carboxybutyryl)-1-beta-D-arabinofuranosylcytosine and chitosan as a macromolecular prodrug of 1-beta-D-arabinofuranosylcytosine.
    Ichikawa H; Onishi H; Takahata T; Machida Y; Nagai T
    Drug Des Discov; 1993; 10(4):343-53. PubMed ID: 8148473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipophilic arabinofuranosyl cytosine derivatives in liposomes.
    Schwendener R; Schott H
    Methods Enzymol; 2005; 391():58-70. PubMed ID: 15721374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of n-squalenoyl cytarabine and evaluation of its affinity with phospholipid bilayers and monolayers.
    Sarpietro MG; Ottimo S; Giuffrida MC; Rocco F; Ceruti M; Castelli F
    Int J Pharm; 2011 Mar; 406(1-2):69-77. PubMed ID: 21219999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism of the new liposomal anticancer drug N4-octadecyl-1-beta-D-arabinofuranosylcytosine in mice.
    Koller-Lucae SK; Suter MJ; Rentsch KM; Schott H; Schwendener RA
    Drug Metab Dispos; 1999 Mar; 27(3):342-50. PubMed ID: 10064564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in sustained release of antineoplastic drugs using liposomes which avoid uptake into the reticuloendothelial system.
    Allen TM; Mehra T
    Proc West Pharmacol Soc; 1989; 32():111-4. PubMed ID: 2780575
    [No Abstract]   [Full Text] [Related]  

  • 16. Synthesis, transport and pharmacokinetics of 5'-amino acid ester prodrugs of 1-beta-D-arabinofuranosylcytosine.
    Sun Y; Sun J; Shi S; Jing Y; Yin S; Chen Y; Li G; Xu Y; He Z
    Mol Pharm; 2009; 6(1):315-25. PubMed ID: 19115956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution and metabolism of lipsome-encapsulated and free 1-beta-D-arabinofuranosylcytosine (Ara-C) in dog and mouse tissues.
    Ellens H; Rustum Y; Mayhew E; Ledesma E
    J Pharmacol Exp Ther; 1982 Aug; 222(2):324-30. PubMed ID: 7097552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N4-Behenoyl-1-beta-D-arabinofuranosylcytosine as a potential new antitumor agent.
    Aoshima M; Tsukagoshi S; Sakurai Y; Oh-ishi JI; Ishida T
    Cancer Res; 1977 Aug; 37(8 Pt 1):2481-6. PubMed ID: 872077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine.
    Horber DH; Schott H; Schwendener RA
    Br J Cancer; 1995 May; 71(5):957-62. PubMed ID: 7734320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of chemotherapeutic effect by entrapping 1-beta-D-arabinofuranosylcytosine in lipid vesicles and its mode of action.
    Kataoka T; Kobayashi T
    Ann N Y Acad Sci; 1978; 308():387-94. PubMed ID: 279298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.